S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
Log in

NASDAQ:NXTC - NextCure Stock Price, Forecast & News

$37.07
+0.13 (+0.35 %)
(As of 03/31/2020 04:00 PM ET)
Today's Range
$35.44
Now: $37.07
$38.67
50-Day Range
$32.32
MA: $41.25
$49.22
52-Week Range
$13.86
Now: $37.07
$109.00
Volume130,112 shs
Average Volume235,616 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for NextCure Inc.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NXTC
CUSIPN/A
CIKN/A
Phone240-399-4900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.35 million
Book Value$14.13 per share

Profitability

Net Income$-33,740,000.00
Net Margins-531.54%

Miscellaneous

EmployeesN/A
Market Cap$1.02 billion
Next Earnings Date6/8/2020 (Estimated)
OptionableNot Optionable

Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.


NextCure (NASDAQ:NXTC) Frequently Asked Questions

How has NextCure's stock been impacted by COVID-19 (Coronavirus)?

NextCure's stock was trading at $38.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NXTC stock has decreased by 3.0% and is now trading at $37.07. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of NextCure?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NextCure.

When is NextCure's next earnings date?

NextCure is scheduled to release its next quarterly earnings announcement on Monday, June 8th 2020. View our earnings forecast for NextCure.

How were NextCure's earnings last quarter?

NextCure Inc (NASDAQ:NXTC) issued its earnings results on Tuesday, November, 12th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.02. The firm had revenue of $1.58 million for the quarter, compared to the consensus estimate of $1.50 million. NextCure had a negative return on equity of 21.84% and a negative net margin of 531.54%. View NextCure's earnings history.

What price target have analysts set for NXTC?

8 brokers have issued 12 month price targets for NextCure's shares. Their forecasts range from $44.00 to $87.00. On average, they expect NextCure's share price to reach $66.50 in the next twelve months. This suggests a possible upside of 79.4% from the stock's current price. View analysts' price targets for NextCure.

Has NextCure been receiving favorable news coverage?

News headlines about NXTC stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NextCure earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutNextCure.

Are investors shorting NextCure?

NextCure saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 1,296,200 shares, an increase of 11.7% from the February 27th total of 1,160,000 shares. Based on an average daily trading volume, of 224,800 shares, the short-interest ratio is presently 5.8 days. Approximately 8.1% of the company's stock are short sold. View NextCure's Current Options Chain.

Who are some of NextCure's key competitors?

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Honeywell International (HON), Amgen (AMGN), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), CVS Health (CVS), AT&T (T), Verizon Communications (VZ), NVIDIA (NVDA), Home Depot (HD) and Altria Group (MO).

When did NextCure IPO?

(NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $37.07.

How big of a company is NextCure?

NextCure has a market capitalization of $1.02 billion and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.  View additional information about NextCure.

What is NextCure's official website?

The official website for NextCure is http://www.nextcure.com/.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]


MarketBeat Community Rating for NextCure (NASDAQ NXTC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  45 (Thanks for Voting!)
Underperform Votes:  34 (Thanks for Voting!)
Total Votes:  79
MarketBeat's community ratings are surveys of what our community members think about NextCure and other stocks. Vote "Outperform" if you believe NXTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: Strike Price

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel